



Emergence of Oxacillin Resistance in Stealth Methicillin-Resistant *Staphylococcus aureus* Due to *mecA* Sequence Instability

Richard V. Goering,^a Erin A. Swartzendruber,^{a*} Anne E. Obradovich,^a Isabella A. Tickler,^b Fred C. Tenover^b

^aDepartment of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska, USA

^bCepheid, Sunnyvale, California, USA

ABSTRACT *Staphylococcus aureus* strains that possess a *mecA* gene but are phenotypically susceptible to oxacillin and ceftiofloxacin (OS-MRSA) have been recognized for over a decade and are a challenge for diagnostic laboratories. The mechanisms underlying the discrepancy vary from isolate to isolate. We characterized seven OS-MRSA clinical isolates of six different *spa* types from six different states by whole-genome sequencing to identify the nucleotide sequence changes leading to the OS-MRSA phenotype. The results demonstrated that oxacillin susceptibility was associated with mutations in regions of nucleotide repeats within *mecA*. Subinhibitory antibiotic exposure selected for secondary *mecA* mutations that restored oxacillin resistance. Thus, strains of *S. aureus* that contain *mecA* but are phenotypically susceptible can become resistant after antibiotic exposure, which may result in treatment failure. OS-MRSA warrant follow-up susceptibility testing to ensure detection of resistant revertants.

KEYWORDS MRSA, emergence of resistance, *mecA*, oxacillin susceptible, whole-genome sequencing

Infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) are an issue of long-standing global concern (1). As with many problem pathogens, efforts to improve both detection and therapeutic outcome now commonly rely on a combination of traditional and molecular approaches (e.g., disk diffusion and PCR, respectively). However, instances may arise where phenotypic and genotypic data appear discrepant. Such is the case with *Staphylococcus aureus* isolates appearing susceptible to oxacillin or ceftiofloxacin by disk diffusion or MIC testing but positive for the *mecA* gene by PCR, commonly termed oxacillin-susceptible MRSA (OS-MRSA) (2, 3). For over a decade clinical OS-MRSA isolates have been reported from various geographic locations, including continental Europe (3–5), the United Kingdom (6), North America (7–9), Asia (10–15), Africa (16), and South America (17, 18). A similar phenomenon has also been seen in livestock-associated and environmental isolates (10, 19, 20). Each report has underscored the diagnostic dilemma such strains represent. However, most studies have not addressed the potential cause(s) of phenotypic-genotypic disparity. Investigations that have examined underlying mechanisms have generally found heterogeneous bacterial populations with either (i) a resistant subset or (ii) induction of resistance among susceptible cells (7, 16, 21). In the present study, a group of North American *S. aureus* clinical isolates with a clear propensity to produce resistant colonies within the zone of inhibition in ceftiofloxacin disk susceptibility tests were analyzed by whole-genome sequencing (WGS) to investigate the nature of the mechanism(s) underlying the OS-MRSA phenotype.

Citation Goering RV, Swartzendruber EA, Obradovich AE, Tickler IA, Tenover FC. 2019. Emergence of oxacillin resistance in stealth methicillin-resistant *Staphylococcus aureus* due to *mecA* sequence instability. *Antimicrob Agents Chemother* 63:e00558-19. <https://doi.org/10.1128/AAC.00558-19>.

Copyright © 2019 Goering et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Richard V. Goering, richardgoering@creighton.edu.

* Present address: Erin A. Swartzendruber, College of Allied Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Received 14 March 2019

Returned for modification 7 April 2019

Accepted 14 May 2019

Accepted manuscript posted online 20 May 2019

Published 25 July 2019

TABLE 1 Characteristics of oxacillin-susceptible MRSA clinical isolates and their MRSA revertants^a

Isolate	Origin (U.S. state)	Source	<i>spa</i> type	SCC <i>mec</i> type	MLST ST/CC	Before exposure to antibiotic			After exposure to antibiotic		
						Oxacillin MIC (μg/ml)	Cefoxitin screen (μg/ml)	PBP2a	Oxacillin MIC (μg/ml)	Cefoxitin screen (μg/ml)	PBP2a
CRG2382	KS	SSTI ^b	t175	IV	ST1/CC1	0.5	≤4	Neg	>2	>4	Pos
CRG2383	KS	SSTI	t175	IV	ST1/CC1	0.5	≤4	Neg	>2	>4	Pos
CRG2935	IA	Nares	t002	IV	ST5/CC5	≤0.25	≤4	Neg	>2	>4	Pos
CRG2937	OR	Blood	t242	II	ST5/CC5	≤0.25	≤4	Neg	>2	>4	Pos
CRG2939	NC	Blood	t2308	II	ST105/CC5	≤0.25	≤4	Neg	1	>4	Pos
CRG2941	TN	Blood	t010	II	ST5/CC5	≤0.25	≤4	Neg	>2	>4	Pos
CRG2943	MS	Blood	t002	IV	ST5/CC5	≤0.25	≤4	Weak Pos	>2	>4	Pos

^aMRSA clinical isolates were *mecA* positive but susceptible to cefoxitin by disk diffusion (zone size, ≥22 mm). MRSA revertants were resistant to cefoxitin by disk diffusion (zone size, ≤21 mm). Pos, positive; Neg, negative.

^bSSTI, skin and soft tissue infection.

RESULTS

The seven OS-MRSA study isolates from six U.S. states represented six *spa* types, three multilocus sequence types (MLST), and two SCC*mec* types (Table 1). Prior to antibiotic exposure, the isolates were determined to be cefoxitin screen negative and oxacillin susceptible by MIC testing, cefoxitin susceptible by disk diffusion testing, PBP2a negative by latex agglutination (isolate CRG2943 was weakly positive), and *mecA* PCR positive. While detailed clinical information was not available, six of the isolates were cultured from active infections two of which (CRG2382 and CRG2383) were from the same hospital but epidemiologically unrelated patients and were previously reported to appear to show “inducible” resistance (7). One isolate (CRG2935) was from a nasal surveillance culture. The four variations of the disk susceptibility testing method were associated with minor differences in the appearance of cefoxitin-resistant isolates. For example, resistant colonies were always more easily detected (i.e., larger colonies appearing earlier during incubation) on brain heart infusion (BHI) medium with a 10⁷ CFU/ml inoculum. This was especially true for CRG2937, CRG2939, and CRG2941, which produced pinpoint colonies within the zones of inhibition at 24 h. After 48 h of incubation, all of the isolates produced colonies within the zones of inhibition of the disks. However, for CRG2382, CRG2383, CRG2935, and CRG2943 the colonies were typically near or at the edge of the zone of inhibition, with standard susceptibility testing using Mueller-Hinton agar (MHA, 10⁵ CFU/ml) giving smaller and less frequently seen numbers of colonies. These colonies were subsequently shown to be resistant by MIC and disk diffusion testing (Table 1). Similar results were observed using either oxacillin or cefazolin disks. To investigate the genetic basis for the resistant colonies detected by disk diffusion, the cefoxitin-susceptible parent strains and their resistant derivatives were analyzed by WGS. Sequence analysis of the *mecA* gene in the isolates (referenced against *S. aureus* MW2; accession number CP026073.1) (Fig. 1) revealed 21 instances of five or more T or A tandem repeats, with additional longer sequences interrupted by only a single alternative base. The seven OS-MRSA isolates exhibited a variety of single point or reading frame mutations (i.e., stop codons) usually associated with tandem repeat sequences (Fig. 1; Table 2) likely due to slip-strand mispairing during DNA replication (22). In each case, exposure to subinhibitory concentrations of antibiotic selected for a corrective secondary mutation (Fig. 1; Table 2), which restored *mecA* function (i.e., PBP2a production) and cefoxitin resistance at frequencies ranging from ~1 × 10⁶ to 1 × 10⁷, which was stable even after five subcultures on drug-free BHI agar. Further WGS data analysis revealed no obvious defects in genes associated with DNA replication, repair, or mutator function which might predispose to the OS-MRSA phenotype. This was also confirmed by assessing the rates of spontaneous mutation to rifampin resistance for each of the isolates (23), which did not differ significantly from conventional MRSA isolates (data not shown), supporting the absence of a mutator genotype.




FIG 1 Comparison of *mecA* sequences in OS-MRSA and MRSA revertants using the wild-type *mecA* sequence from *S. aureus* strain MW2 (CP026073.1) as a template. The location of specific sequence changes are numerically referenced and referred to in Table 2.

DISCUSSION

The diagnostic dilemma posed by OS-MRSA was recently summarized by Tenover and Tickler in a literature survey documenting the presence of such strains in 1 to 25% of the isolates examined (2). While these survey numbers represent OS-MRSA arising by a variety of mechanisms and different susceptibility testing methods, the most problematic are the subset of PBP2a-negative isolates, such as those seen here, which represent true “stealth” MRSA with a high potential for reversion to resistance in the presence of antibiotic. A previous study by Proulx et al. (24) reported an OS-MRSA

TABLE 2 Comparison of *mecA* sequences in OS-MRSA strains and MRSA revertants^a

Isolate ^b	OS-MRSA		MRSA revertant		Position(s) on <i>mecA</i> sequence map
	Relevant <i>mecA</i> sequence	Result	Relevant <i>mecA</i> sequence	Result	
CRG2382	C→T, nt 796	Stop codon replaces glutamine	T→A, nt 796	Lysine replaces stop codon	6
CRG2383	C→T, nt 796	Stop codon replaces glutamine	T→G, nt 796	Glutamic acid replaces stop codon	6
CRG2935	G→A, nt 1673	Stop codon replaces tryptophan	T→A, nt 1672	Lysine replaces stop codon	8, 9
CRG2937	G→A, nt 3	Stop codon replaces methionine	A→G, nt 12	New methionine created (only first three aa lost)	1, 2
CRG2939	Loss of A, nt 255–261	Reading frameshift produces stop codon	Insertion of A, nt 268–272	Reading frame restored	3, 4
CRG2941	Loss of A, nt 662–668	Reading frameshift produces stop codon	Insertion of A, nt 662–668	Reading frame restored	5
CRG2943	Loss of G, nt 692–695	Reading frameshift produces stop codon	Insertion of G, nt 692–695	Reading frame restored	7

^a“Relevant *mecA* sequence” columns indicate the nucleotide change and the change site(s). nt, nucleotide(s); aa, amino acid(s).

^bIsolates CRG2382 and CRG2383 were obtained from different patients during different time periods (7).

isolate with a *mecA* frameshift mutation similar to that seen with isolate CRG2939 reported here. However, our study extends understanding of this issue by demonstrating that such OS-MRSA may be found in a variety of strain backgrounds (e.g., multiple *spa* and MLST types), clinical specimens (blood and wounds), and geographic locations (multiple states in the United States). Events contributing to the initial *mecA* mutations in these OS-MRSA strains leading to phenotypic susceptibility are unknown. However, the “fluid” nature of OS-MRSA reversion is clearly evidenced by isolates such as CRG2382 and CRG2383. Both were from the same health care facility in Kansas but were from different patients and obtained during different time periods. Both isolates had identical *mecA* mutations initially, but they were reversed by different secondary mutations. As noted above and in contrast to Proulx et al. (24), antibiotic exposure at subinhibitory concentrations did select for reversion to resistance. However, previous population analysis of these two isolates (7) demonstrated their pure “MSSA-like” nature, confirming that such strains represent a stable homogeneous genetic background, appearing antibiotic susceptible but with a clear (but masked) potential for emergence of resistance under appropriate conditions. This includes subinhibitory antibiotic concentrations, which can definitely occur in a clinical environment. The “stealth” nature of these MRSA underscores the importance of vigilance with regard to their accurate detection. DNA sequencing is required to reveal the presence of *mecA* mutations, such as those seen here, that render MRSA phenotypically susceptible but fully capable of reversion to resistance when exposed to an antimicrobial agent. However, all OS-MRSA do not have the same genetic basis. Thus, the extent of the sequencing needed to identify mutations responsible for the OS-MRSA phenotype would be broad, which is currently not practical for laboratories performing MIC tests. Tenover and Tickler (2) have recently summarized useful approaches to the general detection of OS-MRSA. For isolates such as those described here, colonies within the zone of inhibition in disk susceptibility tests (especially with enriched medium and extended incubation) are a clue arguing in favor of a provisional report of MRSA since the potential exists for relatively rapid and stable emergence of resistance. While approaches to accurate pathogen diagnosis, characterization, and treatment continue to advance, these data underscore the complex interplay between phenotype and genotype in MRSA strains.

In summary, we have demonstrated that the inherent instability of tandem base repeats within the *S. aureus mecA* sequence can produce “stealth” MRSA (OS-MRSA) in different strain backgrounds and clinical settings. These strains are capable of reversion to resistance by simple and relatively frequent point mutation to restore gene function, underscoring the importance of vigilance in the diagnosis and treatment of these problem pathogens.

MATERIALS AND METHODS

Bacterial isolates. The characteristics of the clinical isolates examined are summarized in Table 1. Determination of *spa* type and SCC*mec* type were performed by published methods (25). PBP2a production was assessed using commercially available products (Oxoid PBP2' latex agglutination test [Oxoid Microbiology Products, Basingstoke, Hampshire, United Kingdom] and Alere PBP2a [Alere, Waltham, MA]). Antimicrobial susceptibility testing was performed using the MicroScan Walkaway Pos MIC Panels type 29 (Beckman Coulter, Brea, CA) according to the manufacturer's instructions. The isolates were also tested using the disk diffusion method, according to Clinical and Laboratory Standards Institute (CLSI) guidelines (26) using cefoxitin disks and interpreted using CLSI M100 A-28 (27). Quality control organisms for antimicrobial susceptibility testing included *Staphylococcus aureus* ATCC 29213, *S. aureus* ATCC 25923, and *S. aureus* ATCC BAA-977 (all methicillin susceptible), as well as ATCC 43300 (MRSA), *Enterococcus faecalis* ATCC 29212, and *Escherichia coli* ATCC 35218.

Conventional and whole-genome sequencing. “Sanger” *mecA* sequence analysis of isolates was performed using previously described primers (28). For WGS, genomic DNA was extracted (DNeasy kit; Qiagen, Germantown, MD), and Nextera XT libraries were sequenced on an MiSeq instrument according to the manufacturer's instructions (Illumina, San Diego, CA). WGS analysis was performed using BioNumerics (v.7.6; Applied Maths, Belgium).

Mutation to antibiotic resistance. To define conditions influencing the production of resistant colonies by the isolates, four variations of cefoxitin disk susceptibility testing were investigated. We used both standard (10^5 CFU/ml) and elevated (10^7 CFU/ml) inocula on MHA (BD Difco, Sparks, MD) and BHI agar (BD Difco) plates that were incubated at 35°C and examined at 24 and 48 h. To determine the

frequency of cefoxitin-resistant derivatives of the OS-MRSA isolates, $\sim 10^7$ cells were inoculated onto BHI agar plates (BD Difco) containing cefoxitin (4 $\mu\text{g/ml}$), which were subsequently replica plated to cefoxitin-containing agar plates (8 $\mu\text{g/ml}$) to confirm resistance. The propensity for an isolate to mutate (i.e., mutator genotype) was assessed by determining the isolate's spontaneous mutation frequency to rifampin resistance as previously described (23).

ACKNOWLEDGMENTS

F.C.T. and I.A.T. are employees of Cepheid. R.V.G. has received research funding from Cepheid.

REFERENCES

- Lakhundi S, Zhang K. 2018. Methicillin-resistant *Staphylococcus aureus*: molecular characterization, evolution, and epidemiology. *Clin Microbiol Rev* 31:1–103. <https://doi.org/10.1128/CMR.00020-18>.
- Tenover FC, Tickler IA. 2015. Is that *Staphylococcus aureus* isolate really methicillin susceptible? *Clin Microbiol News* 37:79–84. <https://doi.org/10.1016/j.clinmicnews.2015.04.004>.
- Kampf G, Adena S, Ruden H, Weist K. 2003. Inducibility and potential role of *mecA* gene-positive oxacillin-susceptible *Staphylococcus aureus* from colonized healthcare workers as a source for nosocomial infections. *J Hosp Infect* 54:124–129. [https://doi.org/10.1016/S0195-6701\(03\)00119-1](https://doi.org/10.1016/S0195-6701(03)00119-1).
- Ikonomidis A, Michail G, Vasdeki A, Labrou M, Karavasilis V, Stathopoulos C, Maniatis AN, Pournaras S. 2008. *In vitro* and *in vivo* evaluations of oxacillin efficiency against *mecA*-positive oxacillin-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother* 52:3905–3908. <https://doi.org/10.1128/AAC.00653-08>.
- Witte W, Pasemann B, Cuny C. 2007. Detection of low-level oxacillin resistance in *mecA*-positive *Staphylococcus aureus*. *Clin Microbiol Infect* 13:408–412. <https://doi.org/10.1111/j.1469-0691.2006.01671.x>.
- Saeed K, Ahmad N, Dryden M, Cortes N, Marsh P, Sitjar A, Wyllie S, Bourne S, Hemming J, Jeppesen C, Green S. 2014. Oxacillin-susceptible methicillin-resistant *Staphylococcus aureus* (OS-MRSA), a hidden resistant mechanism among clinically significant isolates in the Wessex region/UK. *Infection* 42:843–847. <https://doi.org/10.1007/s15010-014-0641-1>.
- Penn C, Moddrell C, Tickler IA, Henthorne MA, Kehrl M, Goering RV, Tenover FC. 2013. Wound infections caused by inducible methicillin-resistant *Staphylococcus aureus* strains. *J Glob Antimicrob Resist* 1:79–83. <https://doi.org/10.1016/j.jgar.2013.03.009>.
- Kong LY, Jean A, Wong H, Semret M, Frenette C, Simor AE, Fenn S, Loo VG. 2015. Bacteremia caused by a *mecA*-positive oxacillin-susceptible *Staphylococcus aureus* strain with inducible resistance. *Diagn Microbiol Infect Dis* 83:377–378. <https://doi.org/10.1016/j.diagmicrobio.2015.09.001>.
- Bearman GM, Rosato AE, Assanasen S, Kleiner EA, Elam K, Haner C, Wenzel RP. 2010. Nasal carriage of inducible dormant and community-associated methicillin-resistant *Staphylococcus aureus* in an ambulatory population of predominantly university students. *Int J Infect Dis* 14(Suppl 3):e18–e24. <https://doi.org/10.1016/j.ijid.2009.09.005>.
- Pu W, Su Y, Li J, Li C, Yang Z, Deng H, Ni C. 2014. High incidence of oxacillin-susceptible *mecA*-positive *Staphylococcus aureus* (OS-MRSA) associated with bovine mastitis in China. *PLoS One* 9:e88134. <https://doi.org/10.1371/journal.pone.0088134>.
- He W, Chen H, Zhao C, Zhang F, Wang H. 2013. Prevalence and molecular typing of oxacillin-susceptible *mecA*-positive *Staphylococcus aureus* from multiple hospitals in China. *Diagn Microbiol Infect Dis* 77:267–269. <https://doi.org/10.1016/j.diagmicrobio.2013.07.001>.
- Song Y, Cui L, Lv Y, Li Y, Xue F. 2017. Characterization of clinical isolates of oxacillin-susceptible *mecA*-positive *Staphylococcus aureus* in China from 2009 to 2014. *J Glob Antimicrob Resist* 11:1–3. <https://doi.org/10.1016/j.jgar.2017.05.009>.
- Chen FJ, Huang IW, Wang CH, Chen PC, Wang HY, Lai JF, Shiau YR, Lauderdale TL. 2012. *mecA*-positive *Staphylococcus aureus* with low-level oxacillin MIC in Taiwan. *J Clin Microbiol* 50:1679–1683. <https://doi.org/10.1128/JCM.06711-11>.
- Hososaka Y, Hanaki H, Endo H, Suzuki Y, Nagasawa Z, Otsuka Y, Nakae T, Sunakawa K. 2007. Characterization of oxacillin-susceptible *mecA*-positive *Staphylococcus aureus*: a new type of MRSA. *J Infect Chemother* 13:79–86. <https://doi.org/10.1007/s10156-006-0502-7>.
- Jannati E, Arzanlou M, Habibzadeh S, Mohammadi S, Ahadi P, Mohammadi-Ghalehbin B, Dogaheh HP, Dibah S, Kazemi E. 2013. Nasal colonization of *mecA*-positive, oxacillin-susceptible, methicillin-resistant *Staphylococcus aureus* isolates among nursing staff in an Iranian teaching hospital. *Am J Infect Control* 41:1122–1124. <https://doi.org/10.1016/j.ajic.2013.02.012>.
- Chung M, Kim CK, Conceicao T, Aires-De-Sousa M, de LH, Tomasz A. 2016. Heterogeneous oxacillin-resistant phenotypes and production of PBP2A by oxacillin-susceptible/*mecA*-positive MRSA strains from Africa. *J Antimicrob Chemother* 71:2804–2809. <https://doi.org/10.1093/jac/dkw209>.
- Andrade-Figueiredo M, Leal-Balbino TC. 2016. Clonal diversity and epidemiological characteristics of *Staphylococcus aureus*: high prevalence of oxacillin-susceptible *mecA*-positive *Staphylococcus aureus* (OS-MRSA) associated with clinical isolates in Brazil. *BMC Microbiol* 16:115–123. <https://doi.org/10.1186/s12866-016-0733-4>.
- Duarte FC, Danelli T, Tavares ER, Morguette AEB, Kerbauy G, Grion CMC, Yamauchi LM, Perugini MRE, Yamada-Ogatta SF. 2018. Fatal sepsis caused by *mecA*-positive oxacillin-susceptible *Staphylococcus aureus*: first report in a tertiary hospital of southern Brazil. *J Infect Chemother* 25:293–297. <https://doi.org/10.1016/j.jiac.2018.09.010>.
- Mistry H, Sharma P, Mahato S, Saravanan R, Kumar PA, Bhandari V. 2016. Prevalence and characterization of oxacillin susceptible *mecA*-positive clinical isolates of *Staphylococcus aureus* causing bovine mastitis in India. *PLoS One* 11:e0162256. <https://doi.org/10.1371/journal.pone.0162256>.
- Quijada NM, Hernández M, Oniciuc E-A, Eiros JM, Fernández-Natal I, Wagner M, Rodríguez-Lázaro D. 2019. Oxacillin-susceptible *mecA*-positive *Staphylococcus aureus* associated with processed food in Europe. *Food Microbiol* 82:107–110. <https://doi.org/10.1016/j.fm.2019.01.021>.
- Forbes BA, Bombicino K, Plata K, Cuirolo A, Webber D, Bender CL, Rosato AE. 2008. Unusual form of oxacillin resistance in methicillin-resistant *Staphylococcus aureus* clinical strains. *Diagn Microbiol Infect Dis* 61:387–395. <https://doi.org/10.1016/j.diagmicrobio.2008.04.003>.
- Bzymek M, Lovett ST. 2001. Evidence for two mechanisms of palindrome-stimulated deletion in *Escherichia coli*: single-strand annealing and replication slipped mispairing. *Genetics* 158:527–540.
- Schaaff F, Reipert A, Bierbaum G. 2002. An elevated mutation frequency favors development of vancomycin resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 46:3540–3548. <https://doi.org/10.1128/aac.46.11.3540-3548.2002>.
- Proulx MK, Palace SG, Gandra S, Torres B, Weir S, Stiles T, Ellison RT, III, Goguen JD. 2016. Reversion from methicillin susceptibility to methicillin resistance in *Staphylococcus aureus* during treatment of bacteremia. *J Infect Dis* 213:1041–1048. <https://doi.org/10.1093/infdis/jiv512>.
- Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Mediavilla JR, Persing DH. 2012. Characterization of nasal and blood culture isolates of methicillin-resistant *Staphylococcus aureus* from patients in United States Hospitals. *Antimicrob Agents Chemother* 56:1324–1330. <https://doi.org/10.1128/AAC.05804-11>.
- Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 13th ed, M2-A13. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement, M100-S8. Clinical and Laboratory Standards Institute, Wayne, PA.
- Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, Kreiswirth BN, Schlievert PM. 2003. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 47:196–203. <https://doi.org/10.1128/aac.47.1.196-203.2003>.